SCHEMBL11943907

SCHEMBL11943907

CCCCCOc1c(N2CCN(S(C)(=O)=O)CC2)cnn(-c2ccccn2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.47
▸ DCTPP1 Q9H773 1/20 0.47
▸ KDM4E B2RXH2 4/20 0.45
▸ MAPT P10636 2/20 0.45
▸ HSD17B10 Q99714 5/20 0.44
▸ MEN1 O00255 5/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ CYP2D6 P10635 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ HPGD P15428 2/20 0.41
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945026 0.91 MEN1 (0.50) ALDH1A1KDM4EMAPTHSD17B10MEN1
SCHEMBL11943902 0.88 ALDH1A1 (0.46) ALDH1A1DCTPP1KDM4EMAPTHSD17B10
SCHEMBL11944984 0.87 ALDH1A1 (0.61) ALDH1A1DCTPP1KDM4EMAPTKMT2A
SCHEMBL11944489 0.84 MEN1 (0.43) ALDH1A1KDM4EMAPTHSD17B10MEN1
SCHEMBL11944001 0.82 ALDH1A1 (0.48) ALDH1A1DCTPP1KDM4EMAPTHSD17B10
SCHEMBL11943870 0.81 MAPT (0.51) ALDH1A1DCTPP1MAPTMEN1KMT2A
SCHEMBL11944233 0.80 ALDH1A1 (0.58) ALDH1A1DCTPP1KDM4EMAPTKMT2A
SCHEMBL11943954 0.80 MEN1 (0.42) ALDH1A1DCTPP1KDM4EMAPTHSD17B10
SCHEMBL11943867 0.80 MAPT (0.64) ALDH1A1DCTPP1KDM4EMAPTHSD17B10
SCHEMBL11944193 0.79 ALDH1A1 (0.45) ALDH1A1DCTPP1KDM4EMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885DCTPP1 625/4885KDM4E 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback